# Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: ORGO
Company: Organogenesis
Source: Organogenesis
Published: 2025-10-31 20:05 EST
Original Source URL: https://investors.organogenesis.com
## Summary

CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine

## Article Body
CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine
## Recent Company News
- 2026-05-07 20:06 EST — [Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2026-financial-results) — Source: Organogenesis
- 2026-04-28 20:30 EST — [Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®](https://biopharmsignal.com/news/ORGO/organogenesis-completes-rolling-submission-of-biologics-license-application-for-renur) — Source: Organogenesis
- 2026-04-06 23:02 EST — [Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM](https://biopharmsignal.com/news/ORGO/organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraplyram) — Source: Organogenesis
- 2026-04-06 11:30 EST — [Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026) — Source: Organogenesis
- 2026-02-26 21:05 EST — [Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue](https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-fourth-quarter-2025-financial-results-posts-record-revenue) — Source: Organogenesis
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)